Angiotensin II induces reactive oxygen species, DNA damage, and T-cell apoptosis in severe COVID-19.

"Disclosure of potential conflict of interest: P. Corbeau received a grant from AbbVie. The rest of the authors declare that they have no relevant conflicts of interest."

"Supported by the 10.13039/501100022656University Hospital of Nîmes (grant NIMAO/2020/COVID/PC-01 [to P.C.]), the Fondation pour la Recherche Médicale, and the 10.13039/501100001665Agence Nationale de Recherche (grant 216261 [to J.E.]). Disclosure of potential conflict of interest: P. Corbeau received a grant from AbbVie. The rest of the authors declare that they have no relevant conflicts of interest."

"This was an observational, monocentric, case-control study. Adults with positive nasopharyngeal swabs for SARS-CoV-2 RNA by RT-PCR were consecutively recruited at the Nîmes University Hospital. Patients were either recruited on the day of their admission to an intensive care unit (ICU) or at admission to the Tropical and Infectious Diseases Department (the non-ICU group). No outlier was excluded. All of the replicates were biologic. This study was approved by the French Ethics Committee, Île-de-France 1. All patients provided written informed consent, and the trial was registered (Eudract/IDRCB identifier 2020-A00875-34 and ClinicalTrials identifier NCT04351711)."